Kornimate/medical-research-clean huggingface dataset:
contribution of echocardiography to prognostic evaluation of pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to determine the prognostic value of echocardiographic parameters in comparison with clinical and hemodynamic parameters in pulmonary arterial hypertension (pah). a secondary purpose of this study is to analyze the disease evolution after 3 to 6 months. in pulmonary fibrosis it has been demonstrated that the variation of clinical and paraclinical parameters between 2 examinations has a prognostic interest. in this study the prognostic value of variation of some echocardiographic parameters between initial examination and echocardiography after 3 or 6 months will be evaluated. another secondary purpose is to create a common database for pneumology, cardiology and epidemiology departments with prospective registration of new cases of pah and follow of patients under treatment.

pulmonary arterial hypertension (pah) is a rare pathology with a poor prognosis and a median survival lower than 3 years in the absence of a specific treatment. the prognostic evaluation is based on clinical and hemodynamic data needing the right cardiac catheterization. it has been shown that prognosis depends essentially on the severity of right ventricular dysfunction. recently, various echocardiographic parameters derived from new techniques such as tissue doppler have been validated for the evaluation of right ventricular function. some have been used as prognostic factor in cardiac insufficiency, but not in pah. this is an observational retrospective and then prospective study. usual pah assessment includes a complete clinical and paraclinical evaluation. history and physical examination assess dyspnea, search signs of disease severity and quantify functional impact of 6 min-walking test. an echocardiography and a right cardiac catheterization are realized in all patients. clinical consultations of patients and control echocardiographic and hemodynamic examinations are programmed at regular intervals. the demonstration of prognostic value of some echocardiographic parameters could diminish right cardiac catheterizations.

Eligibility criteria:
inclusion criteria: * mean pulmonary artery pressure \> 25 mmhg in hemodynamics * according to venice classification: idiopathic pah or associated to other known risk factors (anorectics, portal hypertension, connective tissue diseases, in particular scleroderma but also lupus, congenital heart disease with eisenmenger syndrome, hiv infection) exclusion criteria: * atrial fibrillation * poor echogenicity * pah associated to another factor, thromboembolic disease, respiratory insufficiency, left heart disease or mitral or aortic valvulopathy
evaluating the effectiveness of neupro® (rotigotine) and l-dopa combination therapy in patients with parkinson's disease

Conditions: Idiopathic Parkinson's Disease

Summary: this study aims to evaluate the effectiveness of rotigotine and levodopa combination therapy for younger and older patients with parkinson's disease under real life conditions. effects on ability to perform activities of daily living, sleep, medication dose and other factors will be assessed.


Eligibility criteria:
inclusion criteria: the following selection criteria must be followed for patients entering the noninterventional study (nis): * the decision by the treating physician to prescribe rotigotine transdermal patch is made before participating in the nis due to a clinical therapeutic indication (e.g., because of intolerance and/or ineffectiveness of another dopamine agonist) * the patient is either male or female and over 18 years of age * a patient data consent form is signed and dated by the patient or by the legal representative * the patient has idiopathic parkinson's disease, has not received rotigotine within 28 days prior to the baseline visit and is willing to participate in questionnaire based assessments * the patient is receiving l-dopa as monotherapy or a combination therapy composed of l-dopa and a dopamine agonist other than rotigotine * the patient has been on l-dopa therapy for at least 6 months and is responding to initial l-dopa therapy * the patient has a hoehn and yahr stage score of 1 to 4. exclusion criteria: * patients will be excluded from the study if they have participated in a clinical study of a medication or a medical device within 3 months prior to baseline or if they are participating in a clinical study at the time of inclusion or have already participated in the current study.

Keywords: parkinson's disease neupro® rotigotine transdermal patch neupart levodopa noninterventional combination therapy
driving ability in patients with cmt 1a

Conditions: CMT 1A

Summary: charcot marie tooth 1a (cmt 1a) is a common inherited disorder of the nerves in the body. the disease can result in difficulties with strength and balance as well as in foot deformities such as high arches, hammer toes, and tight ankles. because of these difficulties, the disease may affect driving, especially because driving requires quick responses at times such as slamming on the brakes or turning the steering wheel quickly. the following study determines driving performance in individuals who have cmt 1a.

individuals with cmt 1a will drive in a driving simulator, which involves a car located in a room in the university of iowa hospitals and clinics (uihc). individuals will drive in the car as if they are driving in real life and the whole experience is like playing a car video game with a big animated screen. the driving results will be compared to similar aged patients who don't have cmt 1a and have also taken the driving test. if patients with cmt 1a do have driving difficulties compared to those who do not have cmt 1a, the results of the study will try to help patients with cmt1a drive better by ultimately creating devices that might help them use the steering wheel or brake pedal in a safer way.

Eligibility criteria:
inclusion criteria: * have cmt 1a * have a valid driver's license exclusion criteria: * history of other types of neuropathy (other than cmt 1a) * history of blindness, seizures, or stroke, dementia/cognitive dysfunction
long-term tolerability and safety of hyqvia/hyqvia in cidp

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Summary: adults with chronic inflammatory demyelinating polyradiculoneuropathy (cidp) who have completed study 161403 will be able to take part in this study. the main aim of the study is to evaluate side effects in the long-term treatment with hyqvia/hyqvia. all participants will receive hyqvia/hyqvia in the same way as they were receiving in study 161403. the dosing interval of hyqvia/hyqvia can be adjusted after 12 weeks of treatment in study 161505 if the study doctor determines that it is safe to do so. participants will visit the clinic within 1 week after the first and second dose of hyqvia/hyqvia and then every 12 weeks for the duration of the study.


Eligibility criteria:
inclusion criteria: 1. has completed epoch 1 of study 161403 without cidp worsening. 2. if female of childbearing potential, the participant must have a negative pregnancy test at baseline and agree to employ adequate birth control measures (eg, birth control pills/patches, intrauterine device, or diaphragm or condom \[for male partner\] with spermicidal jelly or foam) throughout the course of the study. exclusion criteria: 1. participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in this extension study. 2. new medical condition that developed during participation in study 161403 that, in the judgment of the investigator, could increase risk to the participant or interfere with the evaluation of investigational medicinal product (imp) and/or conduct of the study. 3. participant is scheduled to participate in another non-baxalta clinical study involving an ip or investigational device during the course of this study. 4. the participant is nursing or intends to begin nursing during the course of the study 5. participant has participated in another clinical study involving an investigational product (ip) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study (with the exception of study 161403) involving an ip or investigational device during the course of this study. 6. the participant is a family member or employee of the investigator.
study for using radiosurgery on limited metastases of breast cancer

Conditions: Breast Cancer, Metastatic

Summary: the purpose of this study is to evaluate whether radiosurgery, along with standard chemotherapy, immunotherapy (the treatment of cancer by modulating the immune system and immune response), or hormonal therapy, affects the quality and length of life. the standard therapy is surgery, radiation therapy, or chemotherapy alone or in any combination. a second purpose of this study is to determine if the levels of a special type of protein (called cytokines) found in the blood are related to the quality of life while on this treatment.

before treatment begins, you will have a physical exam and blood tests. physical evaluations and blood tests will be done each week while you are receiving treatment, and at follow-up visits. you will be seen for follow-up evaluations 4 weeks after treatment is completed, and every three months thereafter. you will be asked to fill out a quality of life questionnaire, which should take 5-10 minutes to complete. this will be done prior to treatment and at your follow-up visits. you will receive high dose radiation therapy directed at the site of metastasis. this treatment will be given once a day, 5 times a week (monday through friday) for one to four weeks depending on the location and size of the disease to be treated.

Eligibility criteria:
inclusion criteria: * age: no limit * karnofsky performance status (kps) ≥ 70 * no more than 5 metastatic sites involving one or more different organs (liver, lung or bone). * the size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol. * previously treated lesions are not eligible unless the prescribed dose can be safely delivered. * concurrent therapy is allowed and recommended. the chemotherapy protocol type and schedule are at the discretion of the medical oncologist. * informed consent must be obtained. * pregnancy test must be negative for women of child bearing potential exclusion criteria: * inability of patient to be followed longitudinally as specified by protocol. * technical inability to achieve required dose based on safe dose constraints required for radiosurgery. * women who are pregnant or nursing. * failure to meet requirements in inclusion criteria * contraindications to radiation.

Keywords: conformal radiotherapy
white spot lesions prevention during orthodontic fixed appliance treatment: a randomized clinical trial

Conditions: White Spot Lesion of Tooth

Summary: the aim of this study is to evaluate the effectiveness of calcium fluoride nanoparticles containing orthodontic primer in preventing or decreasing the incidence wsls over a period of 6 months in patients with fixed orthodontic appliances. this study proposed to be double blinded, split mouth, randomized clinical trial, with equal randomization (1:1 allocation ratio).

the sample was selected and recruited from patients attending two centres (orthodontic department at karbala governmental specialized dental center and almina dental private clinics/karbala), but the bonding and follow up sessions were done in almina dental private clinics/karbala. patient recruitment was done according to specified inclusion and exclusion criteria. intervention procedure planned to be by bonding fixed orthodontic appliances to all patients. the four quadrants of the mouth will be divided into two groups (group 1 and 2), with one group, the upper right and lower left quadrants bonded with ncaf2 resin, while the upper left and lower right quadrants bonded with control resin. for the other group, the reverse will be carried out. then, by the use of a computer random number generator, the two groups will be randomly allocated, and each number in the random table will be given a study number in order to create the final allocation table for the participants in the study (which contained the study number and allocation group). the primary planned to be measured by diagnodent pen 2190 device to measure enamel demineralization objectively, while the secondary objective planned to be quantitative detection of streptococcus mutans bacteria by using real-time pcr

Eligibility criteria:
inclusion criteria: * patients have 1. fully erupted permanent teeth (regardless the third molar), 2. indication to have orthodontic treatment without extraction 3. fair or good oral hygiene before or after oral hygiene instruction exclusion criteria: * patients will be excluded if they had 1. previous orthodontic treatment or extractions 2. missing teeth 3. active enamel caries determined by clinical examination 4. patients with enamel hypoplasia, dental fluorosis or tetracycline pigmentation 5. labial restorations 6. severe periodontal diseases determined according to pdi index by sigurd p. ramfjord (ramfjord, 1967) 7. craniofacial syndromes such as clefts 8. xerostomia determined from clinical history of the patient 9. severely rotated teeth (limiting the appearance of buccal surfaces) 10. heavy smokers determined by accounting the number of cigarettes per day and time to the first cigarette of the day (heatherton et al., 1989) .

Keywords: white spot lesions orthodontic primer calcium fluoride nanoparticles
study on efficacy and safety of lnp023 in c3 glomerulopathy patients transplanted and not transplanted

Conditions: Glomerulonephritis

Summary: the study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of lnp023 in patients with c3g (cohort a) and patients who have undergone kidney transplant and have c3g recurrence (cohort b).


Eligibility criteria:
inclusion criteria for cohort a and b: * written informed consent must be obtained before any assessment is performed * male and female patients between the ages of 18 to 65 (inclusive) at screening * c3g patients wit proteinuria * able to communicate well with the investigator, to understand and comply with the requirements of the study * at screening and baseline visits, patients must weigh at least 35 kg * supine vital signs should be within the following ranges : oral body temperature between 35.0-37.5 °c systolic blood pressure, 80-170 mm hg diastolic blood pressure, 50-105 mm hg pulse rate, 45 - 100 bpm . inclusion criteria for cohort a: * estimated gfr (using the ckd-epi formula) or measured gfr ≥30 ml/min per 1.73 m2 for patients on a maximum recommended or maximum tolerated dose of an angiotensin converting enzyme inhibitor (acei) or angiotensin receptor blocker (arb) * upcr ≥ 100 mg/mmol (equivalent to ≥ 1 g/24h total urinary protein excretion) * prior to entry, all patients must have been on supportive care including a maximally tolerated dose of acei or arb for at least 30 days. inclusion criteria for cohort b: * no histological/laboratory/clinical signs of allorejection * if applicable, induction treatment after allotransplantation needs to be completed \>30 days before inclusion. * transplantation of a kidney allograft \>90 days before inclusion * patients need to be on a stable dose of immunosuppressive regimen prior to inclusion. any approved treatments are allowed for this purpose. exclusion criteria for cohort a and b: * use of other investigational drugs at the time of enrollment, or within 5 half-lives of randomization, or within 30 days, whichever is longer; or longer if required by local regulations * a history of clinically significant ecg abnormalities, * known family history or known presence of long qt syndrome or torsades de pointes * use of agents known to prolong the qt interval unless they can be permanently discontinued for the duration of the study * pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test. * women of child bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of investigational drug. * history of immunodeficiency diseases, or a positive hiv test result. * chronic infection with hepatitis b (hbv) or hepatitis c (hcv). * patients who cannot receive vaccinations against n. meningitidis, s. pneumoniae, or h. influenzae
analgesia for thyroidectomy using bilateral superficial cervical plexus block with bupivacaine only or adding ketorolac to it.

Conditions: Thyroid Goiter; Thyroid Nodule

Summary: thyroidectomy is considered a common operation with moderate to severe postoperative pain in some patients. patients are divided into two groups. bupivacaine group received bilateral superficial cervical plexus block (bscpb) with 10 ml of bupivacaine (0.25%) and 1 ml of normal saline on each side and the bupivacaine ketorolac group received (bscpb) with 10 ml of bupivacaine (0.25%) and 1 ml of ketorolac (15 mg) on each side.


Eligibility criteria:
inclusion criteria: * patients aged 20-50 years * asa i-ii patients * patients going to do thyroid surgeries under general anesthesia exclusion criteria: * patient refusal * known history of sensitivity to the drug used in the study * drug abuse * infection at the site of the block * presence of coagulopathy

Keywords: ketorolac, superficial cervical plexus block, thyroidectomy
comparison of kinesiotaping and graded exposure therapy on kinesiophobia in post-mastectomy patients

Conditions: Post-mastectomy Pain Syndrome

Summary: the aim of this research is to compare the effect of comparison of kinesiotaping and graded exposure therapy on kinesiophobia in post-mastectomy patients. the sample size was 30. the subjects were divided in two groups, 15 subjects in kinesiotaping group and 15 in graded exposure therapy group. study duration was of 1 year. sampling technique applied was nonprobability convenience sampling technique. patients had recently undergone mastectomy procedure age between 30 to 60 years and mean tempa- 11 score of \>23 were included. tools used in the study are tempa -11 for kinesiophobia, nprs for pain, spadi for functional outcome measure. data was be analyzed through spss 26.

mastectomy is a procedure performed as a part of treatment for breast cancer, which entails removal of entire breast tissue. breast cancer is a condition where abnormal cells in the breasts proliferate and eventually develop tumor. it is the most prevalent form of cancer accounting for 23% of all the newly diagnosed cancers. there are several types of mastectomy procedures including complete mastectomy, radical mastectomy and modified radical mastectomy. after mastectomy, many possible complications and side effects can occur including seroma, lymphedema, pain, restricted range of motion, kinesiophobia, infection etc. and all these complications required special care and treatment to improve patient's quality of life. breast cancer survivor often develop fear of movement called kinesiophobia either due to pain or other psychological factors. it is the excessive, irrational, and debilitating fear of movement or physical activity. this fear of movement is linked to a feeling of susceptibility to injury from movement. as a result of using the painful area less due to the fear of increased pain from movement, acute pain can develop into persistent and chronic pain that in return increase hospital stay and decrease quality of life which increase the financial burden on individual. according to the recent studies kinesiophobia is one of the parameters found in post-mastectomy patients with mean tempa -11 score of 24 in pakistani populations. post mastectomy complications are mostly manageable, and studies show significant improvement in patient's symptoms. shoulder disability, pain and rom are addressed in many studies but managing kinesiophobia in early stages after mastectomy still needs to be further discussed

Eligibility criteria:
inclusion criteria: * females * age between 30-60 years. * post-mastectomy patients (not more than 4 weeks). * tempa -11 score \>23. exclusion criteria: * any shoulder dislocations/fracture. * any known neurological impairments i.e. radiculopathy * bilateral mastectomy * known cardiac issues * patients undergoing chemotherapy * any known allergies to kinesiotaping

Keywords: kinesiophobia kinesiotaping graded exposure therapy post-mastectomy patients
liposomal doxorubicin in treating patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of liposomal doxorubicin in treating patients with prostate cancer that has not responded to hormone therapy.

objectives: i. estimate the objective response rate of patients with hormone refractory prostate cancer treated with doxorubicin hcl liposome. ii. determine the toxic effects (including any cumulative cardiotoxicity) of this regimen in these patients. iii. assess the effect of this regimen on pain and quality of life of these patients. outline: patients receive doxorubicin hcl liposome iv over 45 minutes every 3 weeks. treatment continues in the absence of disease progression or unacceptable toxicity. quality of life is assessed at baseline and then every 9 weeks thereafter. patients are followed every 3 months. projected accrual: approximately 50 evaluable patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed hormone refractory prostate cancer castrate serum testosterone levels less than 30 mg/dl occurring at least 4 weeks since prior flutamide or at least 6 weeks since prior bicalutamide measurable or evaluable progressive disease rising psa involving two determinations (one at least 20 ng/ml if psa is sole criterion) at least two weeks apart or increasing measurable or evaluable disease or new metastasis patient characteristics: age: not specified performance status: ecog 0-2 life expectancy: at least 3 months hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 2.0 mg/dl no hepatic insufficiency renal: creatinine no greater than 2.0 mg/dl no renal failure cardiovascular: cardiac ejection fraction at least 50% by radionuclide ventriculogram no myocardial infarction within the past year no active angina no congestive heart failure no arrhythmias requiring medication other: no active peptic ulcers no uncontrolled infection or other serious medical condition that would prevent compliance with chemotherapy no uncontrolled diabetes no spinal cord compression or carcinomatous meningitis prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy no other concurrent chemotherapy endocrine therapy: no concurrent corticosteroid therapy concurrent gonadotropin-releasing hormone analogue allowed radiotherapy: at least 2 months since prior radiotherapy (not to a measurable lesion) concurrent palliative radiotherapy allowed surgery: not specified

Keywords: recurrent prostate cancer